These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 30166207

  • 1. Calculating LDL cholesterol in familial combined hyperlipidemia: Out with the old, in with the new?
    Martin SS.
    Atherosclerosis; 2018 Oct; 277():172-174. PubMed ID: 30166207
    [No Abstract] [Full Text] [Related]

  • 2. Hyperlipidemia in coronary heart disease. 3. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction.
    Hazzard WR, Goldstein JL, Schrott MG, Motulsky AG, Bierman EL.
    J Clin Invest; 1973 Jul; 52(7):1569-77. PubMed ID: 4352458
    [Abstract] [Full Text] [Related]

  • 3. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome.
    Toto RD, Grundy SM, Vega GL.
    Am J Nephrol; 2000 Jul; 20(1):12-7. PubMed ID: 10644862
    [Abstract] [Full Text] [Related]

  • 4. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype.
    Georgieva AM, van Greevenbroek MM, Krauss RM, Brouwers MC, Vermeulen VM, Robertus-Teunissen MG, van der Kallen CJ, de Bruin TW.
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):744-9. PubMed ID: 14751815
    [Abstract] [Full Text] [Related]

  • 5. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
    Schonfeld G, Aguilar-Salina C, Elias N.
    Am J Cardiol; 1998 Feb 26; 81(4A):43B-46B. PubMed ID: 9526813
    [Abstract] [Full Text] [Related]

  • 6. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA.
    Metabolism; 2008 Jun 26; 57(6):796-801. PubMed ID: 18502262
    [Abstract] [Full Text] [Related]

  • 7. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF.
    Am J Cardiol; 1995 Feb 15; 75(5):348-53. PubMed ID: 7856526
    [Abstract] [Full Text] [Related]

  • 8. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.
    Am J Cardiol; 2003 Apr 15; 91(8):956-60. PubMed ID: 12686335
    [Abstract] [Full Text] [Related]

  • 9. A mouse model with features of familial combined hyperlipidemia.
    Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, Serajuddin H, Francone OL, Breslow JL, Tall AR.
    Science; 1997 Jan 17; 275(5298):391-4. PubMed ID: 8994037
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.
    Vázquez M, Zambón D, Hernández Y, Adzet T, Merlos M, Ros E, Laguna JC.
    Br J Clin Pharmacol; 1998 Mar 17; 45(3):265-9. PubMed ID: 9517370
    [Abstract] [Full Text] [Related]

  • 16. Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management.
    Cortner JA, Coates PM, Liacouras CA, Jarvik GP.
    J Pediatr; 1993 Aug 17; 123(2):177-84. PubMed ID: 8345411
    [Abstract] [Full Text] [Related]

  • 17. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG, Patel ST, Falko JM, Newman HA, Hill DS.
    J Clin Endocrinol Metab; 1982 Jun 17; 54(6):1210-5. PubMed ID: 7076797
    [Abstract] [Full Text] [Related]

  • 18. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
    Yeshurun D, Abukarshin R, Elias N, Lanir A, Naschitz JE.
    Clin Ther; 1993 Jun 17; 15(2):355-63. PubMed ID: 8519043
    [Abstract] [Full Text] [Related]

  • 19. Estimation of VLDL cholesterol in hyperlipidemia.
    Wilson PW, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Sprecher DL, Brewer HB.
    Clin Chim Acta; 1985 Oct 15; 151(3):285-91. PubMed ID: 3863729
    [Abstract] [Full Text] [Related]

  • 20. [Familial combined hyperlipidemia].
    Takagi A, Ikeda Y.
    Ryoikibetsu Shokogun Shirizu; 1998 Oct 15; (19 Pt 2):76-9. PubMed ID: 9645012
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.